Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Gastric Stimulator Helps Control Blood Glucose Levels

By LabMedica International staff writers
Posted on 01 Aug 2011
An implantable gastric stimulator could free diabetics from medications and injections, and lose weight during the process. More...


The Diamond implantable gastric stimulator is based on electrodes attached through laparoscopic surgery to the outer stomach muscles, enhancing their contractions, a natural physiological response to eating; these contractions cause the patient to feel sated more quickly during a meal. It also affects the release of hormones form the gastrointestinal (GI) system that influencing hunger, and the absorption and metabolism of nutrients. Initially designed as a treatment for obesity--one of the risk factors for diabetes--the Diamond was also found to be effective independently in controlling blood glucose levels. Patients have also shown improvement in diabetes-associated metabolic conditions such as high blood pressure, cholesterol, and triglycerides.

The Diamond works by enhancing, rather than artificially pacing, stomach contractions; additionally, it is not continuously activated, but rather kicks in only when the eating detection sensor is activated. Implanted during a minimally invasive procedure with about a day's recovery period, the device does not require any action by the patient, apart from a 45-minute weekly recharging. Every three to six months, the patient is examined by a clinical technician to make sure the system is aligned properly with personal physiological patterns. The Diamond gastric simulator is a product of MetaCure (Kfar Saba, Israel), and has received the European Union CE marking of approval.

“We have over 230 patients implanted with it worldwide, and we've seen the system reduces blood glucose levels significantly,” said Lior Teitelbaum, director of business development at MetaCure. “Our solution reduces weight an average of five kilos, improves the blood lipids profile, reduces blood pressure, and can even improve liver function.”

Related Links:

MetaCure




Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
New
Gold Member
Blood-Based Protein Biomarker Solution for Alzheimer's Disease
BG-DTi2000.
New
Microbiology Laboratory Automation Solution
BD Kiestra™ ReadA+BarcodA
All-in-One Molecular System
AIO M160
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: A large, international study led by City of Hope found that the new, investigational liquid biopsy, called PANXEON, was highly sensitive in detecting stage 1 and 2 pancreatic cancer and had a low rate of false positives. The test was also able to identify high-grade dysplasia, a precancerous condition of the pancreas, potentially enabling intervention before cancer develops. (Photo courtesy of City of Hope)

Multi-Biomarker Blood Test Shows Promise for Early Pancreatic Cancer Detection

Pancreatic cancer has the lowest survival rates of any cancer, with only 14% of patients alive five years after diagnosis. The disease is typically discovered after it has spread, and an estimated 90%... Read more

Microbiology

view channel
Image: Graphical Abstract (Jose A. Céspedes, Maria I. Montañez, Isabel M. Jiménez, et al. Magnetic nanoparticles enable clinically relevant in vitro diagnosis of beta-lactam allergy. Materials Today Bio (2026). DOI: 10.1016/j.mtbio.2026.103356)

Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing

Penicillin allergy labels are common in clinical practice, yet many are incorrect and can lead to suboptimal antibiotic choices. Although 8%–25% of people report a penicillin allergy, only 1%–10% are truly... Read more

Pathology

view channel
image Credit: iStock

Tumor Budding Grading May Predict Chemotherapy Benefit in Resected Lung Squamous Cancer

Outcomes after resection for lung squamous cell carcinoma (SqCC) vary substantially, and the uneven benefit of adjuvant chemotherapy complicates postsurgical treatment decisions. Pathologic markers that... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image: The acquisition adds Convergent Genomics’ UroAmp platform and proprietary urinary tumor DNA technology to Veracyte’s portfolio (Photo courtesy of Convergent Genomics)

Veracyte Acquisition Expands Urine-Based Bladder Cancer Monitoring Capabilities

Veracyte, Inc. has acquired Convergent Genomics, expanding its urology diagnostics offerings with the company’s UroAmp platform and proprietary urinary tumor DNA (utDNA) technology. UroAmp has been clinically... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.